NCT05416762View on ClinicalTrials.gov

Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

November 25, 2022

Study Completion Date

November 25, 2022

Conditions
Major Depressive Disorder (MDD
Interventions
DRUG

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg

DRUG

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg

DRUG

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg

Trial Locations (1)

382210

Cliantha Research Limited, Ahmedabad

All Listed Sponsors
lead

Seasons Biotechnology (Taizhou) Co., Ltd.

INDUSTRY